Randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177 Lu or 111 In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).

Authors :: Tagawa, Scott T.
Thomas, Charlene
Adra, Nabil
Zakharia, Yousef
Philips, George
Quinn, David I.
Agarwal, Neeraj
Nordquist, Luke T.
Wulff-Burchfield, Elizabeth Marie
Appleman, Leonard Joseph
Posadas, Edwin Melencio
Christos, Paul J.
Ballman, Karla V.
Nanus, David M.
Osborne, Joseph
Source :: Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, pLBA21-LBA21, 1p
Publication Year :: 2023

Full Text Access

Tools